Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

United Therapeutics Corporation

Healthcare US UTHR

535.81USD
6.64(1.25%)

Last update at 2026-03-10T20:00:00Z

Day Range

525.86548.12
LowHigh

52 Week Range

207.00279.98
LowHigh

Fundamentals

  • Previous Close 529.17
  • Market Cap11941.24M
  • Volume703977
  • P/E Ratio12.74
  • Dividend Yield-%
  • EBITDA1312.80M
  • Revenue TTM2498.30M
  • Revenue Per Share TTM53.18
  • Gross Profit TTM 1784.70M
  • Diluted EPS TTM21.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 950.60M 593.90M 638.90M -165.00000M 758.90M
Minority interest - - - - -
Net income 727.30M 475.80M 514.80M -104.50000M 589.20M
Selling general administrative 416.20M 402.60M 369.00M 275.50M 206.70M
Selling and marketing expenses 70.80M 64.40M 54.90M 60.70M 59.10M
Gross profit 1789.60M 1563.00M 1375.20M 1331.20M 1429.10M
Reconciled depreciation 51.30M 49.90M 49.90M 45.90M 35.90M
Ebit 979.70M 555.90M 593.60M -187.60000M 790.40M
Ebitda 984.70M 614.80M 671.50M -120.80000M 826.30M
Depreciation and amortization 5.00M 58.90M 77.90M 66.80M 35.90M
Non operating income net other 3.30M 56.60M 68.80M 66.80M -32.60000M
Operating income 979.70M 555.90M 593.60M -187.60000M 805.40M
Other operating expenses 956.60M 1129.60M 889.70M 1636.40M 822.40M
Interest expense 32.40M 18.60M 23.50M 44.20M 13.90M
Tax provision 223.30M 118.10M 124.10M -60.50000M 169.70M
Interest income 45.20M 16.70M 28.60M 44.20M 28.60M
Net interest income 12.80M -1.90000M 5.10M 0.00000M 14.70M
Extraordinary items - - - - 1.80M
Non recurring - - - - -
Other items - - - - -
Income tax expense 223.30M 118.10M 124.10M -60.50000M 169.70M
Total revenue 1936.30M 1685.50M 1483.30M 1448.80M 1627.80M
Total operating expenses 809.90M 1007.10M 781.60M 1518.80M 623.70M
Cost of revenue 146.70M 122.50M 108.10M 117.60M 198.70M
Total other income expense net -29.10000M 38.00M 45.30M 22.60M -61.20000M
Discontinued operations - - - - -
Net income from continuing ops 727.30M 475.80M 514.80M -104.50000M 589.20M
Net income applicable to common shares 727.30M 475.80M 514.80M -104.50000M 589.20M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 7167.00M 6044.50M 5169.10M 4615.00M 3913.40M
Intangible assets 80.50M 16.50M 16.60M 130.10M 130.30M
Earning assets - - - - -
Other current assets 166.20M 219.20M 100.40M 88.30M 133.80M
Total liab 1182.20M 1247.80M 1210.20M 1219.80M 1133.00M
Total stockholder equity 5984.80M 4796.70M 3958.90M 3395.20M 2780.40M
Deferred long term liab - 10.50M 6.90M 9.30M 9.30M
Other current liab 71.00M 339.10M 301.60M 319.20M 39.60M
Common stock 0.70M 0.70M 0.70M 0.70M 0.70M
Capital stock 0.70M 0.70M 0.70M 0.70M 0.70M
Retained earnings 6027.10M 5042.30M 4315.00M 3839.20M 3325.20M
Other liab - 76.80M 104.80M 79.40M 67.00M
Good will 33.70M 28.00M 28.00M 28.00M 28.00M
Other assets - 413.50M 370.10M 1559.00M 293.80M
Cash 1207.70M 961.20M 894.80M 738.70M 738.40M
Cash and equivalents - - - - -
Total current liabilities 804.40M 343.20M 305.40M 323.30M 463.00M
Current deferred revenue 327.80M - - - 163.50M
Net debt -507.70000M -161.20000M -94.80000M 61.30M 111.60M
Short term debt 400.00M - - - 250.00M
Short long term debt 400.00M - - - 250.00M
Short long term debt total 700.00M 800.00M 800.00M 800.00M 850.00M
Other stockholder equity -30.20000M -190.80000M -333.80000M -430.50000M -531.30000M
Property plant equipment - 861.50M 780.90M 731.60M 738.50M
Total current assets 3551.00M 3380.30M 2323.60M 2167.20M 1864.50M
Long term investments 1909.80M 1316.20M 1649.90M 1149.60M 767.50M
Net tangible assets - 4752.20M 3914.30M 3237.10M 2622.10M
Short term investments 1786.40M 1877.50M 1035.90M 1096.30M 747.50M
Net receivables 278.90M 220.40M 198.70M 157.40M 151.40M
Long term debt 300.00M 800.00M 800.00M 800.00M 600.00M
Inventory 111.80M 102.00M 93.80M 86.50M 93.40M
Accounts payable 5.60M 4.10M 3.80M 4.10M 9.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -12.80000M -55.50000M -23.00000M -14.20000M -14.20000M
Additional paid in capital - - - - -
Common stock total equity - 0.70M 0.70M 0.70M 0.70M
Preferred stock total equity - - - - -
Retained earnings total equity - 5042.30M 4315.00M 3839.20M 3325.20M
Treasury stock - - - - -2579.20000M
Accumulated amortization - - - - -
Non currrent assets other 151.80M 114.30M 108.20M 169.90M 154.60M
Deferred long term asset charges - - - - -
Non current assets total 3616.00M 2664.20M 2845.50M 2447.80M 2048.90M
Capital lease obligations - - - - -
Long term debt total - 800.00M 800.00M 800.00M 600.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -683.60000M -366.10000M -681.60000M -239.20000M -466.10000M
Change to liabilities 44.50M -12.50000M 38.60M -16.30000M -11.00000M
Total cashflows from investing activities -811.50000M -486.90000M -738.50000M -335.40000M -820.60000M
Net borrowings -7.50000M - -51.70000M 599.30M -13.20000M
Total cash from financing activities 75.40M 44.80M -16.90000M 611.20M 6.30M
Change to operating activities -150.60000M -112.90000M 16.80M -201.90000M 4.70M
Net income 727.30M 475.80M 514.80M -104.50000M 589.20M
Change in cash 66.40M 156.10M 0.30M 69.20M -35.90000M
Begin period cash flow 894.80M 738.70M 738.40M 669.20M 705.10M
End period cash flow 961.20M 894.80M 738.70M 738.40M 669.20M
Total cash from operating activities 802.50M 598.20M 755.70M -206.60000M 778.40M
Issuance of capital stock - - - - 3.90M
Depreciation 51.30M 49.90M 49.90M 45.90M 35.90M
Other cashflows from investing activities 10.90M - 2.40M -12.50000M -170.10000M
Dividends paid - - -4.70000M -4.10000M -
Change to inventory -13.40000M -7.50000M 10.30M 12.90M 9.30M
Change to account receivables -21.70000M -41.30000M -6.00000M 24.40M 121.40M
Sale purchase of stock -11.40000M -10.80000M -3.70000M -2.10000M 19.50M
Other cashflows from financing activities 798.40M 50.00M 36.80M 813.30M 252.40M
Change to netincome 169.60M 246.70M 122.20M 32.90M -24.60000M
Capital expenditures 138.80M 120.80M 59.30M 83.70M 184.40M
Change receivables -21.70000M -41.30000M -6.00000M 24.40M 121.40M
Cash flows other operating 572.20M 272.60M 540.70M -201.90000M 58.20M
Exchange rate changes - - - - -
Cash and cash equivalents changes 66.40M 156.10M 0.30M 69.20M -35.90000M
Change in working capital -141.20000M -174.20000M 59.70M -180.90000M 124.40M
Stock based compensation 106.80M 138.50M 163.80M 45.40M -26.40000M
Other non cash items 58.30M 65.90M -47.00000M -29.70000M 1.80M
Free cash flow 663.70M 477.40M 696.40M -290.30000M 594.00M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
UTHR
United Therapeutics Corporation		 6.64 1.25% 535.81 12.74 10.17 4.70 1.83 3.72 6.24
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation

1000 Spring Street, Silver Spring, MD, United States, 20910

Key Executives

Name Title Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 1955
Mr. Michael I. Benkowitz Pres & COO 1972
Mr. James C. Edgemond CFO & Treasurer 1968
Mr. Paul A. Mahon J.D. Exec. VP, Gen. Counsel & Corp. Sec. 1964
Mr. Dewey Steadman C.F.A. Head of Investor Relations NA
Ms. Holly Hobson Associate VP of HR NA
Kevin T. Gray Sr. VP of Strategic Operations & Logistics NA
Mr. Patrick Poisson Exec. VP of Technical Operations 1968
Mr. Gil Golden Sr. VP & Chief Medical Officer NA
Dr. Leigh Peterson VP of Product Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.